中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

维生素D缺乏与代谢相关脂肪性肝病的关系

罗玲 廖献花 钟碧慧

引用本文:
Citation:

维生素D缺乏与代谢相关脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2022.07.034
基金项目: 

国家自然科学基金资助项目 (81870404)

国家自然科学基金资助项目 (81670518)

国家自然科学基金资助项目 (81170392)

广东省科技计划项目 (2017A020215015)

广东省科技计划项目 (2014A020212118)

广东省医学科研基金 (A2019496)

中国肝炎防治基金会 (TQGB20140083)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:罗玲负责论文撰写; 廖献花协助论文修改; 钟碧慧负责论文指导和审阅。
详细信息
    通信作者:

    钟碧慧,zhongbh@mail.sysu.edu.cn

Research advances in vitamin D deficiency and metabolic associated fatty liver disease

Research funding: 

National Natural Science Foundation of China (81870404);

National Natural Science Foundation of China (81670518);

National Natural Science Foundation of China (81170392);

Guangdong Science and Technology Department (2017A020215015);

Guangdong Science and Technology Department (2014A020212118);

Medical Scientific Research Foundation of Guangdong Province (A2019496);

Chinese Foundation for Hepatitis Prevention and Control (TQGB20140083)

More Information
  • 摘要: 代谢相关脂肪性肝病(MAFLD)为全球第一大慢性肝病,但发病机制仍不明确,尚缺乏有效的治疗药物。介绍了MAFLD患者常伴有维生素D缺乏,维生素D可能通过影响糖脂代谢、炎症信号通路、免疫调节、肠道微生态等多种途径参与MAFLD的发生发展。提出维生素D有望成为MAFLD的治疗药物,临床上需关注MAFLD患者维生素D水平的监测和管理,但其内在机制、具体补充剂量及疗程亟待深入探索。

     

  • 图  1  VDD从多个方面参与MAFLD发生与发展

    注:TLR,Toll样受体。

    Figure  1.  Vitamin D deficiency participates in the occurrence and development of MAFLD through various pathways

  • [1] ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [2] COTTER TG, RINELLA M. Nonalcoholic fatty liver disease 2020: The state of the disease[J]. Gastroenterology, 2020, 158(7): 1851-1864. DOI: 10.1053/j.gastro.2020.01.052.
    [3] ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
    [4] XIAO QQ, WANG MY, FAN JG. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. J Clin Hepatol, 2021, 37(1): 41-45. DOI: 10.3969/j.issn.1001-5256.2021.01.009.

    肖倩倩, 王梦雨, 范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J]. 临床肝胆病杂志, 2021, 37(1): 41-45. DOI: 10.3969/j.issn.1001-5256.2021.01.009.
    [5] ANDERSON JL, MAY HT, HORNE BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population[J]. Am J Cardiol, 2010, 106(7): 963-968. DOI: 10.1016/j.amjcard.2010.05.027.
    [6] MA JT, CAI S, WAN L, et al. Research progress in the effect of vitamin D deficiency on skeletal and extraskeletal health[J]. Chin J Osteoporosis, 2020, 26(1): 109-113. DOI: 10.3969/j.issn.1006-7108.

    马江涛, 柴爽, 万雷, 等. 维生素D缺乏对骨和骨外作用研究进展[J]. 中国骨质疏松杂志, 2020, 26(1): 109-113. DOI: 10.3969/j.Issn.1006-7108.
    [7] PACIFICO L, OSBORN JF, BONCI E, et al. Association between vitamin D levels and nonalcoholic fatty liver disease: Potential confounding variables[J]. Mini Rev Med Chem, 2019, 19(4): 310-332. DOI: 10.2174/1389557518666181025153712.
    [8] van SCHOOR N, LIPS P. Global overview of vitamin D status[J]. Endocrinol Metab Clin North Am, 2017, 46(4): 845-870. DOI: 10.1016/j.ecl.2017.07.002.
    [9] LI M, LV F, ZHANG Z, et al. Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density[J]. Osteoporos Int, 2016, 27(5): 1907-1916. DOI: 10.1007/s00198-015-3475-5.
    [10] WAN B, GAO Y, ZHENG Y, et al. Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)-a population-based study[J]. Endocr J, 2021, 68(6): 631-637. DOI: 10.1507/endocrj.EJ20-0758.
    [11] NELSON JE, ROTH CL, WILSON LA, et al. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF-κB?[J]. Am J Gastroenterol, 2016, 111(6): 852-863. DOI: 10.1038/ajg.2016.51.
    [12] ARAI T, ATSUKAWA M, TSUBOTA A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2019, 51(7): 1036-1042. DOI: 10.1016/j.dld.2018.12.022.
    [13] YANG BB, CHEN YH, ZHANG C, et al. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocrine, 2017, 55(2): 582-590. DOI: 10.1007/s12020-016-1152-x.
    [14] ZHAI HL, WANG NJ, HAN B, et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China))[J]. Br J Nutr, 2016, 115(8): 1352-1359. DOI: 10.1017/S0007114516000386.
    [15] DUTRA J, LISBOA QC, FEROLLA SM, et al. Vitamin D levels are not associated with non-alcoholic fatty liver disease severity in a Brazilian population[J]. Int J Vitam Nutr Res, 2021, 91(5-6): 411-418. DOI: 10.1024/0300-9831/a000667.
    [16] LI L, ZHANG L, PAN S, et al. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population[J]. Dig Dis Sci, 2013, 58(8): 2376-2382. DOI: 10.1007/s10620-013-2658-1.
    [17] BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
    [18] YIN Y, YU Z, XIA M, et al. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism[J]. Eur J Clin Invest, 2012, 42(11): 1189-1196. DOI: 10.1111/j.1365-2362.2012.02706.x.
    [19] ELHAFIZ M, ZHAO G, ISMAIL M, et al. Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(6): 158657. DOI: 10.1016/j.bbalip.2020.158657.
    [20] ROTH CL, ELFERS CT, FIGLEWICZ DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation[J]. Hepatology, 2012, 55(4): 1103-1111. DOI: 10.1002/hep.24737.
    [21] WANG H, ZHANG Q, CHAI Y, et al. 1, 25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats[J]. J Endocrinol Invest, 2015, 38(10): 1083-1091. DOI: 10.1007/s40618-015-0287-6.
    [22] MA M, LONG Q, CHEN F, et al. Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): 513-523. DOI: 10.1016/j.clinre.2019.10.007.
    [23] TANG HQ, LI XT, YAN X, et al. Effect of dihydroxyvitamin D3 in regulating NF-κB and TGF-β1/Smad pathway in mice of non-alcoholic steatohepatitis and liver fibrosis[J]. Med J Natl Defend Forces Northwest China, 2016, 37(8): 497-500. DOI: 10.16021/j.cnki.1007-8622.2016.08.003.

    唐寒秋, 李晓涛, 闫雪, 等. 1, 25-二羟维生素D3通过调节NF-κB和TGF-β1/Smad通路减轻小鼠非酒精型脂肪性肝炎和肝纤维化[J]. 西北国防医学杂志, 2016, 37(8): 497-500. DOI: 10.16021/j.cnki.1007-8622.2016.08.003.
    [24] KAMEN DL, TANGPRICHA V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity[J]. J Mol Med (Berl), 2010, 88(5): 441-450. DOI: 10.1007/s00109-010-0590-9.
    [25] LI HJ, HU SL, LIU Y, et al. Correlation between serum 25 hydroxyvitamin D3 level and peripheral blood T lymphocyte subsets in patients with chronic hepatitis B[J]. Clin J Med Offic, 2022, 50(2): 205-207, 210. DOI: 10.16680/j.1671-3826.2022.02.27.

    栗红江, 胡素玲, 刘洋, 等. 慢性乙型病毒性肝炎患者血清25-羟基维生素D3水平与外周血T淋巴细胞亚群相关性分析[J]. 临床军医杂志, 2022, 50(2): 205-207, 210. DOI: 10.16680/j.1671-3826.2022.02.27.
    [26] DRORI A, ROTNEMER-GOLINKIN D, AVNI S, et al. Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift[J]. BMC Gastroenterol, 2017, 17(1): 130. DOI: 10.1186/s12876-017-0688-4.
    [27] YANG LD, HE H, AN ZM. Role of intestinal flora in metabolic-associated fatty liver disease[J]. J Clin Hepatol, 2021, 37(9): 2231-2235. DOI: 10.3969/j.issn.1001-5256.2021.09.046.

    杨礼丹, 何訸, 安振梅. 肠道菌群在代谢相关脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2021, 37(9): 2231-2235. DOI: 10.3969/j.issn.1001-5256.2021.09.046.
    [28] FAKHOURY H, KVIETYS PR, ALKATTAN W, et al. Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation[J]. J Steroid Biochem Mol Biol, 2020, 200: 105663. DOI: 10.1016/j.jsbmb.2020.105663.
    [29] SU D, NIE Y, ZHU A, et al. Vitamin D signaling through induction of paneth cell defensins maintains gut microbiota and improves metabolic disorders and hepatic steatosis in animal models[J]. Front Physiol, 2016, 7: 498. DOI: 10.3389/fphys.2016.00498.
    [30] KONG M, ZHU L, BAI L, et al. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(9): G883-G893. DOI: 10.1152/ajpgi.00427.2013.
    [31] BARCHETTA I, CIMINI FA, CAVALLO MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): An update[J]. Nutrients, 2020, 12(11): 3302. DOI: 10.3390/nu12113302.
    [32] DONG B, ZHOU Y, WANG W, et al. Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice[J]. Hepatology, 2020, 71(5): 1559-1574. DOI: 10.1002/hep.30937.
    [33] BOZIC M, GUZMÁN C, BENET M, et al. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis[J]. J Hepatol, 2016, 65(4): 748-757. DOI: 10.1016/j.jhep.2016.05.031.
    [34] BARCHETTA I, CAROTTI S, LABBADIA G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus[J]. Hepatology, 2012, 56(6): 2180-2187. DOI: 10.1002/hep.25930.
    [35] NOBILI V, REIF S. Vitamin D and liver fibrosis: let's start soon before it's too late[J]. Gut, 2015, 64(5): 698-699. DOI: 10.1136/gutjnl-2014-308175.
    [36] GUO XF, WANG C, YANG T, et al. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials[J]. Food Funct, 2020, 11(9): 7389-7399. DOI: 10.1039/d0fo01095b.
    [37] LUKENDA ZANKO V, DOMISLOVIC V, TRKULJA V, et al. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab, 2020, 22(11): 2097-2106. DOI: 10.1111/dom.14129.
    [38] GEIER A, EICHINGER M, STIRNIMANN G, et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study[J]. Scand J Gastroenterol, 2018, 53(9): 1114-1120. DOI: 10.1080/00365521.2018.1501091.
    [39] DASARATHY J, VARGHESE R, FELDMAN A, et al. Patients with nonalcoholic fatty liver disease have a low response rate to vitamin D supplementation[J]. J Nutr, 2017, 147(10): 1938-1946. DOI: 10.3945/jn.117.254292.
    [40] TABRIZI R, MOOSAZADEH M, LANKARANI KB, et al. The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials[J]. Diabetes Metab Syndr, 2017, 11(Suppl 2): S975-S982. DOI: 10.1016/j.dsx.2017.07.025.
    [41] DABBAGHMANESH MH, DANAFAR F, ESHRAGHIAN A, et al. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial[J]. Diabetes Metab Syndr, 2018, 12(4): 513-517. DOI: 10.1016/j.dsx.2018.03.006.
    [42] BOUCHER BJ. Why do so many trials of vitamin D supplementation fail?[J]. Endocr Connect, 2020, 9(9): R195-R206. DOI: 10.1530/EC-20-0274.
    [43] EL-SHERBINY M, ELDOSOKY M, EL-SHAFEY M, et al. Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet[J]. Chem Biol Interact, 2018, 288: 65-75. DOI: 10.1016/j.cbi.2018.04.010.
    [44] NAKANO T, CHENG YF, LAI CY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats[J]. J Hepatol, 2011, 55(2): 415-425. DOI: 10.1016/j.jhep.2010.11.028.
    [45] LUGER M, KRUSCHITZ R, KIENBACHER C, et al. Vitamin D3 loading is superior to conventional supplementation after weight loss surgery in vitamin D-deficient morbidly obese patients: A double-blind randomized placebo-controlled trial[J]. Obes Surg, 2017, 27(5): 1196-1207. DOI: 10.1007/s11695-016-2437-0.
  • 加载中
图(1)
计量
  • 文章访问数:  501
  • HTML全文浏览量:  173
  • PDF下载量:  54
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-11-16
  • 录用日期:  2022-01-14
  • 出版日期:  2022-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回